Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
BUSINESS OF BIOTECHNOLOGY
They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.
Business of Biotechnology is part of Business Exchange, suggested by
Arlene Weintraub.
This topic contains
1,248 news
and
4,696 blog
items.
Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from
like-minded professionals.
Blogs
Recent blog posts on this topic.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology...
The list of biotechs going public grows longer. With public investors warming to biotech IPOs, Portola Pharmaceuticals...
There's Cambridge, and then there's Kendall Square, arguably the heart of all biotech activity in the Boston area.
Chimerix sped out of the IPO gate on Thursday. The Durham, NC-based drug developer's ($CMRX) stock soared on its first...
With pharma groups hunting for external innovation, an analysis shows a spike in early-stage biotech partnerships...
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad)...
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.
GlaxoSmithKline investigator John Kraus reviewed the long-awaited mid-stage results for its Duchenne muscular dystrophy...
With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $30...
Score another big win for Greater Boston's growing biotech hub. Bristol-Myers Squibb ($BMY)--which startled the...
Omthera has priced its IPO of 8 million shares at $8 apiece, forced to offer a deep discount on the $12 to $14 range...
Shares of Acadia Pharmaceuticals ($ACAD) shot up 44% this morning after the San Diego-based biotech announced that the...
David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to...
South San Francisco-based VistaGen Therapeutics says it's raised $36 million, selling shares to Bergamo Acquisition for...
Let's face it: When it comes to new drug approvals, projected blockbuster revenue is one of the sexiest aspects of the...
The FDA has endorsed Pfizer's ($PFE) high hopes for the breast cancer drug palbociclib (or PD-0332991), handing out its...
After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy (DMD)...
Novartis ($NVS) faces an M&A decision that has profound implications for the small biotech Proteon Therapeutics.
Top Sources: Business of Biotechnology
- Biotech Blog
- News
- Health Beat
- frontendofinnovation.blogspot.com
- Nature Biotechnology
- The Biotech Weblog
- policyinnovations.org
- Science Progress
- LinkedIn Answers: Technology
- World Pharma News / Published News
account